Hope Rugo named director of City of Hope’s Women’s Cancers Program

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

Weight-associated breast cancer risk is higher in women with cardiovascular disease, IARC analysis shows

Excess weight is linked to an especially high risk of developing breast cancer in postmenopausal women with cardiovascular disease, according to research from the International Agency for Research on Cancer. The study was published in Cancer.

July 11, 2025

Vol.51 No.27

Scaling excellence: How City of Hope is transforming cancer care delivery

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

July 03, 2025

Vol.51 No.26

By Alan H. Bryce and Walter M. Stadler

Clinical Roundup

Scientists uncover new approach for targeting aggressive breast cancer

A recent study from cancer researchers at the University of Alabama at Birmingham and Georgia State University has identified a new therapeutic target in quadruple-negative breast cancer, or QNBC, one of the deadliest and most aggressive treatment-resistant forms of breast cancer.

July 03, 2025

Vol.51 No.26

Clinical Roundup

City of Hope launches AI tool to reduce burden of cancer care

City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials, and empower breakthrough research.

June 27, 2025

Vol.51 No.25

From “undruggable” target to clinical potential: The journey of AOH1996

When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

June 20, 2025

Vol.51 No.24

By Linda Malkas